Transcriptomics

Dataset Information

0

T cell intrinsic immunomodulatory effects of TAK-981 in chronic lymphocytic leukemia patient derived T cells

ABSTRACT: Transcriptome analysis of TAK981 or DMSO pre-treated chronic lymphocytic leukemia patient derived T cells upon TCR engagement

ORGANISM(S): Homo sapiens

PROVIDER: GSE209744 | GEO | 2024/07/25

REPOSITORIES: GEO

Json Xml

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

Unknown T Cell-intrinsic Immunomodulatory Effects of TAK-981 (Subasumstat), a SUMO-activating Enzyme Inhibitor, in Chronic Lymphocytic Leukemia.
| S-EPMC10525033 | biostudies-literature
Genomics T cell intrinsic immunomodulatory effects of TAK-981 in chronic lymphocytic leukemia patient derived T cells
| PRJNA862282 | ENA
Transcriptomics TAK-981
2021-04-23 | GSE173118 | GEO
Genomics TAK-981
| PRJNA723842 | ENA
Unknown TAK-981, a SUMOylation inhibitor, suppresses AML growth immune-independently.
| S-EPMC10338213 | biostudies-literature
Unknown Quantitation of TAK-981 in human plasma via LC-MS/MS and its application in clinical trials.
| S-EPMC12367096 | biostudies-literature
Unknown TAK-981 potentiates doxorubicin immunocide in triple-negative breast cancer by IFN I-dependent NK cell stimulation.
| S-EPMC12698820 | biostudies-literature
Unknown Intra-tumoral YAP and TAZ heterogeneity drives collective NSCLC invasion that is targeted by SUMOylation inhibitor TAK-981.
| S-EPMC11544388 | biostudies-literature
Genomics Mus musculus
| PRJNA89999 | ENA
Transcriptomics Expression data of chronic lymphocytic leukemia patient samples from the REACH study
2014-07-30 | GSE58211 | GEO